(CercleFinance.com) – Pharnext announced on Monday that it has completed the recruitment of patients in its phase III trial dedicated to Charcot-Marie-Tooth disease type 1A, in accordance with the planned schedule.
This study devoted to PXT3003, the company’s most advanced program, should make it possible to evaluate the efficacy and safety of the treatment over a period of 15 months in the mild to moderate forms of the disease.
Patients enrolled in the randomized, double-blind, placebo-controlled trial (two arms) were recruited from 52 centers in the United States, Canada, Europe and Israel.
The total number of patients exceeded the target of 350 patients, as defined in the protocol.
The first results should be announced during the fourth quarter of 2023.
PXT3003, which comes as an oral solution taken twice daily, is believed to improve the conduction of nerve impulses from damaged peripheral nerves.
This combination has shown promising results in preclinical and Phase II and Phase III clinical studies.
CMT1A affects approximately 1.5 million people worldwide.
Copyright (c) 2022 CercleFinance.com. All rights reserved.
Are you following this action?
Receive all the information about PHARNEXT in real time: